Product
JS004 + Toripalimab
1 clinical trial
1 indication
Indication
Hodgkin lymphomaClinical trial
A Phase III, Randomised, Open-label,, Multi-Center Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1 Monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)Status: Recruiting, Estimated PCD: 2025-05-31